Trial record 1 of 1 for:    NCT00782002
Previous Study | Return to List | Next Study

Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00782002
Recruitment Status : Completed
First Posted : October 29, 2008
Last Update Posted : September 30, 2010
Information provided by:
ImClone LLC

Brief Summary:
The purpose of this study is to determine if IMC-18F1 is safe for patients, and also to determine the best dose of IMC-18F1 to give to patients.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Biological: IMC-18F1 Phase 1

Detailed Description:
The purpose of this study will be to establish the safety profile and the maximum tolerated dose (MTD) of the anti-VEGFR-1 monoclonal antibody IMC-18F1 administered weekly, every other week, or every three weeks in patients with advanced solid tumors who have not responded to standard therapy or for whom no standard therapy is available.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 27 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Study of Weekly Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) Monoclonal Antibody IMC-18F1 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or For Whom No Standard Therapy is Available
Study Start Date : July 2006
Actual Primary Completion Date : March 2009
Actual Study Completion Date : November 2009

Arm Intervention/treatment
Experimental: IMC-18F1 Biological: IMC-18F1
Cohorts 1-4 will receive IMC-18F1 intravenously for 4 weekly infusions, followed by a 2-week observation period. Cohort 5 will receive IMC-18F1 intravenously every other week for the first 6 weeks of therapy. Cohort 6 will receive IMC-18F1 every 3 weeks for the first 6 weeks for therapy. The starting dose in Cohort 1 will be 2mg/kg. The maximum dose of IMC-18F1 will not exceed 16mg/kg administered every week, 15mg/kg administered every other week, and 20mg/kg administered every 3 weeks. Dose escalation of 100% (2 x previous dose) if no dose limiting toxicities (DLTs) are observed in the first three patients within a cohort during the initial 6-week therapy period. Dose escalation increment will be reduced to 50% (1.5 x previous dose) following the occurrence of either grade 2 or higher AEs in 2 or more patients that are possibly, probably, or definitely-related to study medication or one DLT during the initial 6-week therapy period. No intrapatient dose escalation is allowed.

Primary Outcome Measures :
  1. Maximum Tolerated Dose [ Time Frame: 6 weeks ]

Secondary Outcome Measures :
  1. Pharmacokinetics [ Time Frame: 6 weeks ]
  2. Antitumor Activity of IMC-18F1 Monotherapy [ Time Frame: 6 Weeks ]
  3. Pharmacodynamics [ Time Frame: 6 Weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with histopathologically-documented, measurable or non measurable {evaluable}, advanced solid tumors refractory to standard therapy or for which no standard therapy is available (see Section 10.2, Tumor Response, for the definition of measurable and non measurable {evaluable} disease).
  2. Eastern Cooperative Oncology Group (ECOG) performance status score of ≤2 at study entry.
  3. Able to provide written informed consent.
  4. Age 18 years or older.
  5. A life expectancy of >3 months.
  6. Adequate hematologic function, as defined by:

    • an absolute neutrophil count ≥1500/mm3
    • a hemoglobin level ≥ 9gm/dL
    • a platelet count ≥100,000/mm3
  7. Adequate hepatic function, as defined by:

    • a total bilirubin level ≤1.5 x the ULN
    • aspartate transaminase (AST) and alanine transaminase (ALT) levels ≤2.5 x the ULN or ≤5 x the ULN if known liver metastases
  8. Adequate renal function, as defined by a serum creatinine level ≤1.5 x the ULN.
  9. Use of effective contraception (per the institutional standard), if procreative potential exists.
  10. Adequate recovery from recent surgery, chemotherapy, and radiation therapy. At least 28 days must have elapsed from major surgery, prior chemotherapy, prior treatment with an investigational agent or device, or prior radiation therapy (palliative radiation therapy is allowed).
  11. Accessible for treatment and follow-up. Patients enrolled in this trial must be treated at the participating center.

Exclusion Criteria:

  1. Patients who have had chemotherapy or therapeutic radiotherapy within 28 days prior to entering the study or patients with ongoing side effects ≥ grade 2 due to agents administered more than 28 days earlier.
  2. Uncontrolled intercurrent illness including, but not limited to:

    • ongoing or active infection requiring parenteral antibiotics
    • symptomatic congestive heart failure (class III or IV of the New York Heart Association classification for heart disease)
    • left ventricular ejection fraction (LVEF) of <50%. If a baseline MUGA shows a <50% ejection fraction, then a confirmatory ultrasound should be performed. If it is <50%, the patient is excluded from the study
    • unstable angina pectoris, angioplasty, stenting, or myocardial infarction within 6 months
    • uncontrolled hypertension (systolic blood pressure >150 mm Hg, diastolic blood pressure >100 mm Hg, found on two consecutive measurements separated by a 1-week period despite adequate medical support)
    • clinically significant cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or requires treatment [Common Terminology Criteria for Adverse Events {CTCAE}, Version 3.0, grade 3] or asymptomatic sustained ventricular tachycardia)
    • uncontrolled diabetes
    • psychiatric illness/social situations that would compromise patient safety or limit compliance with study requirements
  3. Patients with progressive or symptomatic brain or leptomeningeal metastases. (Patients with a history of brain metastases must have received definitive surgery or radiotherapy, be clinically stable, and not taking steroids; anti-seizure medications are allowed).
  4. A serious or nonhealing active wound, ulcer, or bone fracture.
  5. Known human immunodeficiency virus positivity.
  6. A major surgical procedure, an open biopsy, or a significant traumatic injury within 28 days prior to treatment.
  7. Current or recent use (within 28 days) of a thrombolytic agent.
  8. Current use of full-dose warfarin (an exception is low-dose warfarin to maintain patency of pre-existing, permanent, indwelling intravenous (i.v.) catheters; for patients receiving warfarin, the international normalized ratio [INR] should be <1.5), heparin or fractionated heparin are excluded.
  9. Chronic daily treatment with aspirin (>325 mg/day), nonsteroidal antiinflammatory or other medications known to inhibit platelet function (cyclooxygenase-2 [COX-2] inhibitors are permitted).
  10. A history or clinical evidence of a deep venous or arterial thrombosis (including pulmonary embolism) within 6 months prior to study entry.
  11. Proteinuria ≥2+ by routine urinalysis or dipstick and subsequent documentation by 24-hour urine collection of >1 g protein. Patients with genitourinary malignancies and/or those with a requirement for urinary catheters or stents will be excluded if the 24-hour urine protein is ≥2 g.
  12. Pregnant (confirmed by serum beta human chorionic gonadotropin [βHCG]) or breast feeding.
  13. Positive for anti-IMC-18F1 antibodies.
  14. Treatment with monoclonal antibodies within 6 weeks of study entry.
  15. A history of allergic reactions to monoclonal antibodies or other therapeutic proteins.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00782002

United States, Michigan
ImClone Investigational Site
Detroit, Michigan, United States, 48201
United States, Ohio
ImClone Investigational Site
Cleveland, Ohio, United States, 44106
Sponsors and Collaborators
ImClone LLC
Study Director: E-mail: ClinicalTrials@ ImClone LLC

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Chief Medical Officer, ImClone LLC Identifier: NCT00782002     History of Changes
Other Study ID Numbers: 13941
CP14-0501 ( Other Identifier: ImClone, LLC )
I4Y-IE-JCDA ( Other Identifier: Eli Lilly and Company )
First Posted: October 29, 2008    Key Record Dates
Last Update Posted: September 30, 2010
Last Verified: September 2010

Keywords provided by ImClone LLC:
Solid Tumors
stromal cells
endothelial cells
malignant cells

Additional relevant MeSH terms:
Endothelial Growth Factors
Growth Substances
Physiological Effects of Drugs